Welcome to our dedicated page for NRNVF news (Ticker: NRNVF), a resource for investors and traders seeking the latest updates and insights on NRNVF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NRNVF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NRNVF's position in the market.
Nordic Nanovector ASA announced positive outcomes from the LYMRIT 37-05 Phase 1 trial of Betalutin® for patients with relapsed/refractory diffuse large B-cell lymphoma. The study demonstrated good tolerance and safety, with no new dose-limiting toxicities after the initial cohort. Clinical activity was observed in 6 patients, including one complete response. The company is evaluating combination therapies for further development. The DLBCL market is expected to grow significantly, with increasing need for effective treatments.
Nordic Nanovector ASA announced the allocation of restricted stock units (RSUs) to its board of directors as detailed in a previous stock exchange notice from June 2, 2021. The move is part of the company's commitment to align the interests of its directors with those of shareholders. The company is focused on developing innovative therapies for cancer care, notably its lead candidate Betalutin®, targeting non-Hodgkin's lymphoma, a market projected to reach nearly USD 26 billion by 2028. This strategic decision aims to enhance leadership commitment and support future growth.
Nordic Nanovector ASA (OSE: NANOV) reported Q1 2021 results, revealing revenues of NOK 0.0 million and operating expenses of NOK 101.2 million. Despite the ongoing COVID-19 pandemic, patient recruitment for the PARADIGME study has improved, with 83 patients enrolled by May 25, 2021. The company raised approximately NOK 422 million (USD 49.7 million) in funding, extending its cash runway into H2 2022. The anticipated preliminary data from PARADIGME is expected by the end of 2021, potentially marking a significant value inflection point for shareholders.
Nordic Nanovector ASA (OSE: NANOV) reported initial data from the Archer-1 Phase 1b trial, evaluating Betalutin® in conjunction with rituximab for second-line follicular lymphoma. The study showed significant clinical activity, with all seven patients responding—five achieving complete responses and two partial responses—some ongoing for up to two years. The safety profile was favorable, similar to Betalutin® alone, with no dose-limiting toxicities. The trial aims to establish Betalutin® as a viable treatment for patients facing relapsed or refractory disease.
Nordic Nanovector ASA will report its first quarter 2021 results on May 26, 2021. A live presentation by the senior management team will be webcast at 8:30am CET on the same day. The webcast can be accessed from www.nordicnanovector.com. The results report and presentation will be available from 7:00am CEST on that day. Nordic Nanovector focuses on developing innovative therapies for haematological cancers, with its lead candidate, Betalutin®, designed to treat non-Hodgkin's lymphoma, a market projected to reach USD 26 billion by 2028.
On March 26, 2021, the Board of Directors of Nordic Nanovector ASA approved its 2020 financial statements. The annual report highlights Nordic Nanovector's commitment to developing innovative cancer therapies, particularly its lead candidate, Betalutin®, aimed at treating non-Hodgkin's lymphoma. The non-Hodgkin's lymphoma market is projected to reach USD 26 billion by 2028. Nordic Nanovector retains global marketing rights for Betalutin® and plans to actively engage in its commercialization in major markets. The annual report is available on the company's website.
Nordic Nanovector announced its financial calendar for 2021, including key dates for upcoming reports. The Extraordinary General Meeting is set for March 22, 2021, followed by the Annual Report on March 26, 2021. The Annual General Meeting will take place on April 28, 2021, with subsequent quarterly and half-yearly reports scheduled throughout the year. Nordic Nanovector focuses on advancing cancer therapies, particularly Betalutin®, targeting non-Hodgkin's lymphoma, which has a projected market worth nearly USD 26 billion by 2028.
Nordic Nanovector ASA (OSE: NANOV) reports improved patient enrollment in its pivotal Phase 2b trial, PARADIGME, for Betalutin® in 3rd-line relapsed/refractory follicular lymphoma. Enrollment increased from approximately 2 to 5 patients per month, potentially rising to 7 by late spring. As of February 17, 2021, 73 patients were enrolled, with 47 more needed for regulatory submission. The trial protocol has been approved in all 24 participating countries, and the company is optimistic about delivering preliminary top-line data in H2 2021.
